<DOC>
	<DOCNO>NCT00000643</DOCNO>
	<brief_summary>To evaluate effectiveness pyrimethamine ( give leucovorin calcium versus placebo ( inactive substance ) primary prophylaxis ( prevention ) cerebral toxoplasmosis HIV-infected patient . Cerebral toxoplasmosis one frequently encounter opportunistic infection course AIDS . The mortality ( death ) rate estimate great 50 percent . Pyrimethamine drug appear promising primary prevention cerebral toxoplasmosis HIV-infected patient .</brief_summary>
	<brief_title>Primary Prophylaxis Cerebral Toxoplasmosis HIV-Infected Patients</brief_title>
	<detailed_description>Cerebral toxoplasmosis one frequently encounter opportunistic infection course AIDS . The mortality ( death ) rate estimate great 50 percent . Pyrimethamine drug appear promising primary prevention cerebral toxoplasmosis HIV-infected patient . AMENDED : 04-04-91 On first day therapy , load dose give . After first day , patient take pyrimethamine placebo 3 time week . Patients also take leucovorin calcium orally three time weekly . Enrollment occur approximately 12 month . All patient follow study common study close-out date final analysis study . It anticipate common close-out occur mean duration time study therapy 3 year ( approximately January , 1994 ) . ORIGINAL design : On first day treatment , patient receive load dose pyrimethamine placebo , plus leucovorin calcium . After first day , patient take pyrimethamine placebo three time week . Patients also take folinic acid orally three time weekly . The mean duration study participation 3 year .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Cerebral</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) , erythropoietin ( Eprex ) , agent grant Treatment IND expand access status . Investigational triazoles . Pentamidine primary prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Patients follow exclude : History cerebral toxoplasmosis toxoplasmosis infection organ tissue . Focal neural abnormality ( except peripheral neuropathy ) mass lesion previous computerized tomography ( CT ) scan magnetic resonance image ( MRI ) , unless subsequent workup rule toxoplasmosis , case abnormality must stable least 2 month . Known suspect allergy severe intolerance study drug . Patients must : Positive toxoplasma serology . HIV infection . Willingness ability comply protocol capability give write informed consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Current diagnosis cerebral toxoplasmosis toxoplasmosis infection organ tissue . Known suspected allergy severe intolerance study drug . Concurrent Medication : Excluded : Anticoagulants . Other antifolates , sulfonamide , fansidar , macrolides , 5fluorouracil , dapsone , agent know activity Toxoplasma gondii .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Toxoplasmosis</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Brain Diseases</keyword>
</DOC>